JWJunhua Wang

Junhua Wang

*This is an algorithmically generated author record based on publicly available information.

Junhua Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between craniosynostosis and phospholipid metabolism: Insights from single-cell and transcriptomic analysis

    by Kaisai Tuerxun, Junhua Wang, Zhimin Huang, Yuqi Zhang

    : Craniosynostosis is a common defect in the craniofacial structure of children, yet its pathogenesis remains unclear. Current research focuses mainly on bone-related genetic mutations, with less emphasis on lipid metabolism disorders. Hence, it is imperative to investigate the underlying mechanisms from various perspectives. We investigated the association between craniosynostosis and phospholipid metabolism through a multi-omics approach. This included Mendelian randomization (MR) to assess causal relationships of lipid traits, transcriptomic differential analysis of clinical samples, and single-cell RNA sequencing of murine cranial sutures to identify key cell subtypes. Furthermore, drug-target MR and network pharmacology were conducted to explore the potential therapeutic repurposing of statins. MR analysis revealed a significant protective effect of phospholipids in very low-density lipoprotein remnants against craniosynostosis. Drug-target MR targeting HMGCR indicated a protective trend (OR = 0.79) for statins, consistent with the lipid-metabolic link, although statistical significance was limited by sample size. Transcriptomic analysis identified MORN5 as a key upregulated gene enriched in glycerophospholipid metabolism. Single-cell RNA sequencing identified a specific osteogenic subtype (C4) and lipid-metabolic subtypes (C5/C6) driving the disease. Pharmacological prediction and molecular docking further suggested that Rosuvastatin could target MORN5 and epidermal growth factor receptor, showing high binding affinity (<−5 kcal/mol). Our findings provide robust evidence that phospholipid metabolism plays a critical role in craniosynostosis. While the genetic evidence for statins is exploratory, the consistent protective trend and molecular docking results suggest a potential therapeutic avenue that warrants further investigation in larger cohorts and experimental models.

  • Identification of Hub Genes in Atypical Teratoid/Rhabdoid Tumor by Bioinformatics Analyses

    by Xin Pan, Wei Liu, Yi Chai, Libo Hu, Junhua Wang, Yuqi Zhang

    Atypical teratoid/rhabdoid tumor (ATRT) is a devastating intracranial tumor in children. Currently, its molecular mechanisms cannot be studied effectively because patient samples are limited, and many factors are involved in its pathogenesis. In this study, we analyzed three gene expression profile data sets obtained from the Gene Expression Omnibus (GEO) database to identify genes that participate in ATRT. The datasets were integrated and analyzed using the RobustRankAggreg method to screen for differentially expressed genes (DEGs). We identified 197 DEGs, including 94 downregulated and 103 upregulated genes which were then used for gene set enrichment analysis. The results showed that the downregulated genes were mainly enriched in synaptic vesicle cycle, nicotine addiction, and GABAergic synapse, whereas the upregulated genes were enriched in the cell cycle, p53 signaling pathway, and cellular senescence. Consistent with these results, gene set enrichment analysis showed that E2F targets, G2M checkpoints, and MYC targets were significantly enriched in datasets. Protein-protein interaction (PPI) network revealed that CDK1, CCNA2, BUB1B, CDC20, KIF11, KIF20A, KIF2C, NCAPG, NDC80, NUSAP1, PBK, RRM2, TPX2, TOP2A, and TTK were hub genes. NetworkAnalyst algorithm was used to predict the transcription factor (TF), and the results showed that MYC, SOX2, and KDM5B could regulate these hub genes. In conclusion, the present study brings a new perspective of ATRT pathogenesis and the strategy targeted to cell cycle related gene may be promising treatments for the disease.